From WikiMD

Monoclonal antibody
SourceTemplate:Infobox drug/mab source
TargetComplement component 5
Gene therapy
Clinical data
Trade namesUltomiris
Other namesALXN1210
Routes of
intravenous infusion
ATC code
Physiological data
Legal status
Legal status
  • In general: rx only
Pharmacokinetic data
Metabolismvarious proteases
CAS Number
  • none
E number{{#property:P628}}
CompTox Dashboard (EPA)
  • {{#property:P3117}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Molar mass144.9 g/mol g·mol−1
Data page

Ravulizumab (ALXN1210) (INN:[1] Ultomiris) is a humanized monoclonal antibody designed for the treatment of paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.

This drug was developed by Alexion Pharmaceuticals, Inc.[2]

It was approved by the US Food and Drug Administration in December 2018.[3] In April 2019, the European CHMP of EMA recommended the granting of a conditional marketing authorisation for ravulizumab.[4]


W8MD weight loss logo

Ad. Tired of being overweight?. W8MD's insurance Weight loss program can HELP*

Quick links: Medicine Portal | Encyclopedia‏‎‏‎ | Gray's Anatomy‏‎ | Topics‏‎ |‏‎ Diseases‏‎ | Drugs | Wellness | Obesity‏‎ | Metabolic syndrome | Weight loss*
Disclaimer: The entire contents of WIKIMD.ORG are for informational purposes only and do not render medical advice or professional services. If you have a medical emergency, you should CALL 911 immediately! Given the nature of the wiki, the information provided may not be accurate, misleading and or incorrect. Use the information on this wiki at your own risk! See full Disclaimer.
Link to this page: <a href="http://www.wikimd.org/wiki/Ravulizumab">Ravulizumab</a>

  • Individual results may vary for weight loss from our sponsors.